NEW TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA

摘要

FIELD: medicine.;SUBSTANCE: present invention refers to immunology. What is presented is using Blinatumomab (MT103) for preparing a pharmaceutical composition for treating, relieving or eliminating acute lymphoblastic leukaemia (ALL), wherein Blinatumomab (MT103) transforms a MRD (minimal residual disease) positive acute lymphoblastic leukaemia ALL into the MRD-negative condition of ALL.;EFFECT: using the invention provides transforming the MRD-positive acute lymphoblastic leukaemia ALL into the MRD-negative condition of ALL molecularly that can find application in medicine in the therapy of recurrent ALL.;21 cl, 8 dwg, 1 tbl, 1 ex